Tesamorelin vs Ipamorelin: Research Comparison
A Side-By-Side Research Comparison Of Tesamorelin And Ipamorelin - a GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Compound Class | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy | Selective synthetic pentapeptide GH secretagogue (GHRP); minimal cortisol/prolactin side effects |
| Evidence Tier | Approved Drug | Research Compound |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism | GHS-R1a (ghrelin receptor) agonist; highly selective for pituitary GH release without significant ACTH/cortisol elevation |
| Molecular Weight | 5135.9 Da | 711.85 Da |
| Amino Acid Sequence | hGHRH(1-44) with trans-3-hexenoyl | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 218949-48-5 | 170851-70-4 |
| Half-Life | ~26-38 minutes | ~2 hours |
| Studied For | HIV-associated lipodystrophy (FDA approved), Hepatic fat / NAFLD research, Cognition research in aging/HIV, GH deficiency | GH secretagogue research, Anti-aging / longevity via GH axis, Body composition improvement, Lean muscle gain |
About Tesamorelin
An FDA-approved growth-hormone-releasing hormone analog used to reduce visceral fat in HIV-associated lipodystrophy; banned in sport.
Read The Full Tesamorelin MonographAbout Ipamorelin
A selective, clean growth-hormone-releasing peptide; banned in sport.
Read The Full Ipamorelin MonographKey Differences
- Evidence tier differs: Tesamorelin is classified as Approved Drug; Ipamorelin is classified as Research Compound.
- Reported half-life differs: Tesamorelin at ~26-38 minutes versus Ipamorelin at ~2 hours.
- Primary molecular target differs: Tesamorelin acts on GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism; Ipamorelin acts on GHS-R1a (ghrelin receptor) agonist; highly selective for pituitary GH release without significant ACTH/cortisol elevation.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.